3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
58
Sarcoma
39
Neoplasm Metastasis
22
Neoplasms
20
Ovarian Neoplasms
17
Breast Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Recurrence
7
Leiomyosarcoma
7
Kidney Neoplasms
7
Melanoma
6
Liposarcoma
6
Hemangiosarcoma
6
Glioblastoma
6
Fallopian Tube Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Neurofibrosarcoma
5
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Sarcoma, Synovial
4
Pancreatic Neoplasms
4
Osteosarcoma
4
Histiocytoma, Malignant Fibrous
4
Dermatofibrosarcoma
4
Clear-cell metastatic renal cell carcinoma
4
Chondrosarcoma, Extraskeletal Myxoid
4
Uterine Cervical Neoplasms
3
Solid Tumors
3
Small Cell Lung Carcinoma
3
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Letrozole
22
Radiotherapy
21
Doxorubicin
21
Megestrol Acetate
20
lenvatinib
19
olaparib
18
Taxes
17
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Metformin
15
Magnetic Resonance Spectroscopy
15
dostarlimab
14
Gemcitabine
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
Biopsy
11
temsirolimus
10
abemaciclib
10
atezolizumab
9
Radiation
9
Everolimus
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endometrial Neoplasms
×
pazopanib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled